查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1671812

经皮贴片市场：市场机会、贴片剂量、定价、临床试验趋势（2030年）

Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 300 Pages | 商品交期: 最快1-2个工作天内

价格

到2030年，全球经皮贴片市场价值预计将达到 180亿美元。目前，美国占据全球经皮贴片市场的主导地位，价值超过 40亿美元。预计到2030年，中国将成为经皮贴片的成长市场。

全球经皮贴片市场正迅速转变为一个充满活力且竞争激烈的领域，新兴公司和老牌公司都在不断创新以满足患者日益成长的需求。这些贴片有助于透过皮肤控制、稳定地释放治疗剂，以治疗各种疾病，包括疼痛管理、戒烟和荷尔蒙替代疗法。一个显着的成功例子是尼古丁贴片，它在 21 世纪初作为一种戒烟辅助工具而广受欢迎。从那时起，经皮贴片治疗的疾病范围大大扩展，现在包括治疗注意力不足过动症、荷尔蒙缺乏症、噁心等。虽然经皮贴片往往比传统药物传递方法更昂贵，但其良好的安全性和有效性一直推动着市场成长。

监管部门的批准对于全球经皮贴片市场的扩张非常重要。获得监管部门的批准对于确保经皮贴片作为药物传递方法的可靠性非常重要。例如，Zydus Lifesciences 于2024年 8月获得了 FDA 的最终批准，其东莨菪碱经皮系统用于治疗噁心和呕吐。同样，中国生物製药于2024年 9月获得 NMPA 批准，其利凡斯的明经皮贴片配方可用于治疗轻度至中度阿兹海默症。此次核准是国产卡巴拉汀贴片首个在华获批上市，更是经皮贴片在全球获得认可的重要指标。

随着药物输送系统的不断创新，经皮贴片的商业可行性得到极大增强。例如，Anodyne Nanotech 的HeroPatch™ 平台已实现 GLP-1 受体促效剂（包括semaglutide）经皮给药的生物利用度超过 50%，并已显示出良好的临床前结果。这项进步有可能替代传统注射透过提供无针、每週一次的方法来改变糖尿病等慢性疾病的管理。 HERO Patch™ 的临床试验预计将于2025年开始，这将强化经皮贴片作为药物传递技术关键组成部分的作用。

目前有几种经皮贴片进行临床试验，凸显了这种药物传递方法的巨大潜力。这些贴片多个治疗领域进行研究，包括慢性疼痛管理、糖尿病治疗、甚至疫苗接种。目前全球已有近 70 种经皮贴片获得核准，市场成长轨迹显得强劲。仍存在一些挑战，例如皮肤刺激和单一贴片输送高剂量药物的局限性，但研究人员在解决这些问题方面取得进展。经皮贴片的前景看好，药物配方、贴片设计和患者依从性的持续改进预计将进一步推动市场成长。

本报告研究了全球经皮贴片市场，并概述了市场以及医药趋势、临床试验趋势、区域趋势以及进入市场的公司的竞争格局。

目录

第1章 经皮贴片简介

第2章 经皮贴片的分类

  • 黏合剂中的单层/多层药物
  • 储库经皮贴剂
  • 基质为基础的经皮贴片
  • 蒸气贴片
  • 主动和被动贴片

第3章 经皮贴片的药物传递机制

  • 经皮治疗药物的特点
  • 经皮贴片的成分
  • 晕动病机转、尼古丁、女性经皮避孕贴片
  • 经皮贴片与传统药物传递方法的比较

第4章 全球经皮贴片市场前景

  • 当前市场状况
  • 未来市场机会

第5章 依区域的全球透皮贴片市场趋势

  • 美国
  • 欧洲
  • 中国
  • 日本
  • 韩国
  • 英国

第6章 依公司、适应症和阶段全球贴片临床新产品线

  • 研究
  • 临床前
  • 第一阶段
  • 第一/第二阶段
  • 第二阶段
  • 第三阶段
  • 预先註册
  • 已註册

第7章 全球上市经皮贴片的临床见解

第8章 心血管疾病经皮贴片 - 市场可用性、剂量与定价分析

  • Nitroglycerin经皮贴片
  • Clonidine经皮贴片
  • Bisoprolol经皮贴片（Bisono）

第9章 经皮止痛贴片 - 市场可用性、剂量与定价分析

  • Fentanyl经皮贴片
  • Buprenorphine经皮贴片
  • Diclofenac经皮贴片
  • Ketoprofen经皮贴片（Mohrus）
  • Lidocaine经皮贴剂
  • Capsaicin经皮贴片（Qutenza）
  • Methyl Salicate经皮贴片
  • Glycol Salicylate经皮贴片（Tokuhon E）
  • Flurbiprofen经皮贴剂

第10章 荷尔蒙治疗中的经皮贴片－市场可用性、剂量与定价分析

  • 雌二醇经皮贴片
  • 睪固酮经皮贴片（Androderm）
  • 雌二醇/炔诺酮经皮贴剂
  • 雌二醇/左旋诺孕酮经皮贴剂
  • 乙炔雌二醇/左炔诺孕酮（Twirla）
  • 乙炔雌二醇/孕二烯酮（Apleek）

第11章 神经系统疾病中的经皮贴片－市场可用性、剂量与定价分析

  • Scopolamine经皮贴片（Transderm-Scop）
  • Selegiline经皮贴片（Emsam）
  • Methylphenidate经皮贴片（Daytrana）
  • Dextroamphetamine经皮贴片（Xelstrym）
  • Blonanserin经皮贴片（Lonasen）
  • Asenapine经皮贴片（Secuado）
  • Rivastigmine经皮贴剂
  • Rotigotine经皮贴片（Neupro）
  • Ropinirole Hydrochloride（Haruropi Tape）
  • Donepezil经皮贴片（Adlarity）

第12章 其他病症的贴片 - 市场供应、剂量与定价分析

  • Nicotine经皮贴片（Nicoderm CQ/Nicotinell TTS）
  • Oxybutynin经皮贴片（Oxytrol/Kentera）
  • Granisetron经皮贴片（Sancuso）
  • Emedastine经皮贴片（Allesaga）
  • Fibrin Sealant密封剂经皮贴剂
  • 5-Aminolevulinic Acid经皮贴片（Alacare）
  • Tulobuterol经皮贴剂

第13章 全球经皮贴片市场动态

第14章 竞争格局

  • AbbVie
  • Bayer HealthCare Pharmaceuticals
  • Corium International
  • Endo Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Luye Pharma
  • Noven Pharmaceuticals
  • Novartis
  • Purdue Pharma
  • Scilex Pharmaceuticals
  • Searchlight Pharma
  • Somerset Pharmaceuticals
  • Teikoku Seiyaku
  • Teva Pharmaceuticals
  • UCB
  • DURECT Corporation
  • Senju Pharmaceutical

Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030 Report Highlights & Findings:

  • Global Transdermal Patch Market Opportunity: US$ 18 Billion By 2030
  • US Currently Dominating Global Transdermal Patch Market: > US$ 4 Billion
  • China To Emerge Growing Market For Transdermal Patches By 2030
  • Currently More Than 60 Patches Are Approved Globally
  • Approved Patches Market Availability, Dosage & Price Analysis
  • Global Transdermal Market Insights By Region & Indications
  • Comprehensive Insight On Clinical Trials By Company, Indication & Phase
  • Competitive Landscape: Insight On Key Companies

The global market for transdermal patches has rapidly transformed into a dynamic and intensely competitive arena, where both emerging players and established firms are continually innovating to address the increasing demands of patients. These patches facilitate a controlled and consistent release of therapeutic agents through the skin, serving a diverse array of medical conditions, including pain management, smoking cessation, hormone replacement therapy, and more. An outstanding example of their success is the nicotine patch, which gained popularity as a smoking cessation aid in the early 2000s. Since then, the spectrum of conditions treated by transdermal patches has broadened considerably, now encompassing treatments for ADHD, hormone deficiencies, and nausea, among others. Although they tend to be pricier than conventional drug delivery methods, transdermal patches are witnessing consistent market growth, propelled by their advantageous safety and efficacy profiles.

An essential element in the ongoing expansion of the global transdermal patch market is the attainment of regulatory approval. Successful validations from regulatory authorities are crucial in affirming the credibility of transdermal patches as a viable drug delivery system. For example, Zydus Lifesciences received the final FDA approval for its scopolamine transdermal system aimed at treating nausea and vomiting in August 2024. Likewise, Sino Biopharmaceutical obtained NMPA approval in September 2024 for its rivastigmine transdermal patch, intended for the treatment of mild to moderate Alzheimer's disease. This approval represents a significant achievement, as it is the first domestically manufactured rivastigmine patch authorized for sale in China, emphasizing the increasing acceptance of transdermal patches on a global scale.

The commercial viability of transdermal patches is further enhanced significantly by ongoing innovations in drug delivery systems. For instance, Anodyne Nanotech's HeroPatch(TM) platform has demonstrated encouraging preclinical outcomes in the transdermal administration of GLP-1 receptor agonists, including semaglutide, achieving over 50% bioavailability. This advancement has the potential to transform the management of chronic diseases such as diabetes by providing a needle-free, weekly alternative to traditional injections. Clinical trials for the HeroPatch(TM) are anticipated to commence in 2025, reinforcing the role of transdermal patches as a pivotal element in drug delivery technology.

In another momentous development, researchers at Central South University in China have created a long-acting transdermal delivery system for Guanfacine, a non-stimulant medication for ADHD. This patch is designed to enhance drug release and ensure skin safety, with the capability of supporting treatment cycles lasting up to three days, thus offering a more convenient and patient-centric solution. Furthermore, Biotts, a Polish company specializing in drug delivery, is developing an insulin transdermal patch utilizing its MTC-Y carrier technology. This innovation allows for insulin delivery over a period of up to five days, providing a stable and extended alternative to the daily injections typically required by individuals with type 1 diabetes. Positive results from animal studies have been reported, and Biotts aims to begin human trials by 2027, which could significantly improve diabetes management for countless patients.

At present, there are multiple transdermal patches undergoing clinical trials, highlighting the significant potential of this method for drug delivery. These patches are being investigated across a growing array of therapeutic areas, such as chronic pain management, diabetes treatment, and even vaccination. With nearly 70 transdermal patches already receiving global approval, the market's growth trajectory appears strong, driven by technological advancements and an expanding spectrum of treatable conditions via transdermal means. Although challenges remain, including skin irritation and limitations in delivering higher drug dosages through a single patch, researchers are making progress in addressing these issues. The outlook for transdermal patches is promising, with ongoing enhancements in drug formulation, patch design, and patient adherence anticipated to further propel market growth.

In conclusion, transdermal patches are on the verge of becoming a widely accepted drug delivery method, providing considerable advantages in terms of patient convenience, reliable therapeutic delivery, and minimized side effects. As the market continues to grow, the clinical and commercial success of transdermal patches is expected to significantly influence the global pharmaceutical landscape, offering patients and healthcare providers more effective, less invasive, and more user-friendly alternatives to conventional drug delivery systems.

Table of Contents

1. Introduction To Transdermal Patch

  • 1.1 Overview Of Transdermal Patch
  • 1.2 Relevance Of Transdermal Patch

2. Transdermal Patches Classification

  • 2.1 Single/ Multiple Layer Drug In Adhesive
  • 2.2 Reservoir Transdermal Patches
  • 2.3 Matrix Based Transdermal Patches
  • 2.4 Vapor Patch
  • 2.5 Active & Passive Patch

3. Mechanism Of Transdermal Patch Drug Delivery

  • 3.1 Properties Of Transdermal Therapeutics
  • 3.2 Components Of Transdermal Patch
  • 3.3 Mechanism Of Motion Sickness, Nicotine & Female Contraceptive Transdermal

Patch

  • 3.4 Transdermal Patch v/s Traditional Drug Delivery Methods

4. Global Transdermal Patch Market Outlook

  • 4.1 Current Market Scenario
  • 4.2 Future Market Opportunity

5. Global Transdermal Patch Market Trends By Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 China
  • 5.4 Japan
  • 5.5 South Korea
  • 5.6 UK

6. Global Patch Clinical Pipeline By Company, Indication & Phase

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Phase-I
  • 6.4 Phase-I/II
  • 6.5 Phase-II
  • 6.6 Phase-III
  • 6.7 Preregistration
  • 6.8 Registered

7. Global Marketed Transdermal Patch Clinical Insight

8. Transdermal Patches For Cardiovascular Diseases - Market Availability, Dosage & Price Analysis

  • 8.1 Nitroglycerin Transdermal Patch
    • 8.1.1 Nitro-Dur
    • 8.1.2 Nitro TD Patch A
    • 8.1.3 Generic Nitroglycerin Transdermal Patch
  • 8.2 Clonidine Transdermal Patch
    • 8.2.1 Catapres-TTS
    • 8.2.2 Generic Clonidine Transdermal Patch
  • 8.3 Bisoprolol Transdermal Patch (Bisono)

9. Transdermal Analgesic Patches - Market Availability, Dosage & Price Analysis

  • 9.1 Fentanyl Transdermal Patch
    • 9.1.1 Duragesic/Durogesic
    • 9.1.2 Durotep MT
    • 9.1.3 OneDuro
    • 9.1.4 Generic Fentanyl Transdermal Patch
    • 9.1.5 Fentos
    • 9.1.6 Fentadur
    • 9.1.7 Generic Fentanyl Citrate Transdermal Patch
  • 9.2 Buprenorphine Transdermal Patch
    • 9.2.1 Butrans
    • 9.2.2 Bunov
    • 9.2.3 Sevodyne
    • 9.2.4 Transtec
    • 9.2.5 Generic Buprenorphine Transdermal Patch
  • 9.3 Diclofenac Transdermal Patch
    • 9.3.1 Zicthoru
    • 9.3.2 Flector
    • 9.3.3 Licart
  • 9.4 Ketoprofen Transdermal Patch (Mohrus)
  • 9.5 Lidocaine Transdermal Patch
    • 9.5.1 Versatis
    • 9.5.2 ZTlido
    • 9.5.3 Penles
    • 9.5.4 Rapydan
  • 9.6 Capsaicin Transdermal Patch (Qutenza)
  • 9.7 Methyl Salicate Transdermal Patch
    • 9.7.1 Salonpas
    • 9.7.2 Tokuhon
  • 9.8 Glycol Salicylate Transdermal Patch (Tokuhon E)
  • 9.9 Flurbiprofen Transdermal Patch
    • 9.9.1 Loqoa
    • 9.9.2 Yakuban Tape
    • 9.9.3 Transact Lat

10. Transdermal Patch In Hormonal Therapy - Market Availability, Dosage & Price Analysis

  • 10.1 Estradiol Transdermal Patch
    • 10.1.1 Alora
    • 10.1.2 Vivelle-Dot
    • 10.1.3 Minivelle
    • 10.1.4 Climara
    • 10.1.5 Menostar
    • 10.1.6 FemSeven
    • 10.1.7 Estrana
    • 10.1.8 Generic Estradiol Transdermal Patch
  • 10.2 Testosterone Transdermal Patch (Androderm)
  • 10.3 Estradiol/ Norethisterone Transdermal Patch
    • 10.3.1 Xulane/Ortho Evra
    • 10.3.2 Combipatch
    • 10.3.3 Menoaid Combi Patch
    • 10.3.4 Evorel Conti
  • 10.4 Estradiol/Levonorgestrel Transdermal Patch
  • 10.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
  • 10.6 Ethinyl Estradiol/Gestodene (Apleek)

11. Transdermal Patches For Neurological Disorders - Market Availability, Dosage & Price Analysis

  • 11.1 Scopolamine Transdermal Patch (Transderm-Scop)
  • 11.2 Selegiline Transdermal Patch (Emsam)
  • 11.3 Methylphenidate Transdermal Patch (Daytrana)
  • 11.4 Dextroamphetamine Transdermal Patch (Xelstrym)
  • 11.5 Blonanserin Transdermal Patch (Lonasen)
  • 11.6 Asenapine Transdermal Patch (Secuado)
  • 11.7 Rivastigmine Transdermal Patch
    • 11.7.1 Exelon
    • 11.7.2 Generic Rivastigmine Transdermal Patch
  • 11.8 Rotigotine Transdermal Patch (Neupro)
  • 11.9 Ropinirole Hydrochloride (Haruropi Tape)
  • 11.10 Donepezil Transdermal Patch (Adlarity)

12. Patches For Other Conditions - Market Availability, Dosage & Price Analysis

  • 12.1 Nicotine Transdermal Patch (Nicoderm CQ/ Nicotinell TTS)
  • 12.2 Oxybutynin Transdermal Patch (Oxytrol/Kentera)
  • 12.3 Granisetron Transdermal Patch (Sancuso)
  • 12.4 Emedastine Transdermal Patch (Allesaga)
  • 12.5 Fibrin Sealant Transdermal Patch
    • 12.5.1 Evarrest
    • 12.5.2 TachoSil
  • 12.6 5-Aminolevulinic Acid Transdermal Patch (Alacare)
  • 12.7 Tulobuterol Transdermal Patch
    • 12.7.1 Tulo-Touch
    • 12.7.2 Hokunarin

13. Global Transdermal Patch Market Dynamics

  • 13.1 Favorable Market Parameters
  • 13.2 Commercialization Challenges

14. Competitive Landscape

  • 14.1 AbbVie
  • 14.2 Bayer HealthCare Pharmaceuticals
  • 14.3 Corium International
  • 14.4 Endo Pharmaceuticals
  • 14.5 Hisamitsu Pharmaceutical
  • 14.6 Luye Pharma
  • 14.7 Noven Pharmaceuticals
  • 14.8 Novartis
  • 14.9 Purdue Pharma
  • 14.10 Scilex Pharmaceuticals
  • 14.11 Searchlight Pharma
  • 14.12 Somerset Pharmaceuticals
  • 14.13 Teikoku Seiyaku
  • 14.14 Teva Pharmaceuticals
  • 14.15 UCB
  • 14.16 DURECT Corporation
  • 14.17 Senju Pharmaceutical

List of Figures

  • Figure 1-1: Transdermal Permeation - Steps Involved
  • Figure 1-2: Transdermal Patch - Ideal Properties
  • Figure 2-1: Commercially Available Transdermal Patch Types
  • Figure 2-2: Multilayer Transdermal Patch
  • Figure 2-3: Reservoir Transdermal Patch System
  • Figure 2-4: Matrix Based Transdermal Patches
  • Figure 3-1: Transdermal Therapeutics - Properties
  • Figure 3-2: Transdermal Patch - Components
  • Figure 3-3: Permeation Enhancer - Types
  • Figure 3-4: Iontophoresis - Schematic Representation
  • Figure 3-5: Scopolamine Transdermal Patch - Mechanism
  • Figure 3-6: Nicotine Transdermal Patch - Mechanism
  • Figure 3-7: Female Contraceptive Transdermal Patch - Mechanism
  • Figure 3-8: Traditional Drug Delivery Methods - Challenges
  • Figure 3-9: Transdermal Patch - Advantages
  • Figure 3-10: Consistent Drug Supply By Transdermal Patch
  • Figure 4-1: Global - Transdermal Patch Market Size (US$ Billion), 2024 - 2030
  • Figure 4-2: Global Transdermal Patch Market By Region (US$ Billion), 2024
  • Figure 4-3: Global Transdermal Patch Market By Region (%), 2024
  • Figure 4-4: Global Transdermal Patch Market By Region (US$ Billion), 2030
  • Figure 4-5: Global Transdermal Patch Market By Region (%), 2030
  • Figure 8-1: Nitro-Dur - Price Per Unit & Supply Of Transdermal Films (US$), March'2025
  • Figure 8-2: Nitro TD Patch A - Price Per Unit & Supply Of Transdermal Films (US$), February'2025
  • Figure 8-3: Generic Nitroglycerin Transdermal Patch - Price Per Unit & Supply (US$), February'2025
  • Figure 8-4: Catapres-TTS - FDA Approval & First Generic Approval Year
  • Figure 8-5: Catapres-TTS - Price Per Unit & Supply (US$), February'2025
  • Figure 8-6: Catapres-TTS Transdermal Patch - Recommended Initial & Incremented Dose (mg/Week)
  • Figure 8-7: Generic Clonidine Transdermal Patch - Price Per Unit & Supply (US$), February'2025
  • Figure 8-8: Bisono - Approval Year By Indication
  • Figure 8-9: Bisono - Price Per Unit By Dose (US$), February'2025
  • Figure 8-10: Bisono - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 9-1: Duragesic - Approval Year By Region
  • Figure 9-2: Durotep MT - Price Per Unit By Dose (US$), February'2025
  • Figure 9-3: OneDuro - Price Per Unit By Dose (US$), February'2025
  • Figure 9-4: Generic Fentanyl Transdermal Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-5: Fentos - Price Per Unit By Dose (US$), February'2025
  • Figure 9-6: Fentos - Annual Sales (US$), 2020-2024
  • Figure 9-7: Generic Fentanyl Citrate Transdermal Patch - Price Per Unit By Dose (US$), February'2025
  • Figure 9-8: Butrans - FDA Approval Year By Dose
  • Figure 9-9: US - Butrans FDA Approval & 1st Generic Approval Year
  • Figure 9-10: Butrans - Approval Year By Region
  • Figure 9-11: Butrans - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-12: Butrans - Initial & Maximum Recommended Dose (mcg/hr)
  • Figure 9-13: Butrans - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 9-14: Bunov - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 9-15: Sevodyne - Price Per Supply (US$), February'2025
  • Figure 9-16: Transtec - Price Per Supply In UK (US$), February'2025
  • Figure 9-17: Generic Buprenorphine Transdermal Patch - Price Per Unit & Supply In US (USS), March'2025
  • Figure 9-18: Zicthoru - Price Per Unit & Supply (US$), February'2025
  • Figure 9-19: Zicthoru - Annual Sales (US$), 2021-2024
  • Figure 9-20: Branded & Generic Flector Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-21: Licart - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-22: Mohrus - Price Per Supply By Dose (US$), February'2025
  • Figure 9-23: Mohrus - Annual Sales (US$), 2020-2024
  • Figure 9-24: Versatis - Price Per Supply By Region (US$), February'2025
  • Figure 9-25: ZTlido - Price Per Unit & Supply (US$), February'2025
  • Figure 9-26: Qutenza - Price Per Unit By Region (US$), February'2025
  • Figure 9-27: Salonpas - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-28: Generic Methyl Salicylate Patch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 9-29: Tokuhon - Price Per Supply (US$), February'2025
  • Figure 9-30: Yakuban Tape - Price Per Supply Of 60mg Tape (US$), February'2025
  • Figure 9-31: Yakuban Tape - Price Per Supply Of 20mg Tape (US$), February'2025
  • Figure 9-32: TransAct Lat - Price Per Supply By Online Pharmacy (US$), February'2025
  • Figure 10-1: Alora - FDA Approval Year By Dose
  • Figure 10-2: Alora - Recommended Dose For Treatment Of Vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice In A Week)
  • Figure 10-3: Vivelle-Dot - FDA Approval & First Generic Approval Year
  • Figure 10-4: Vivelle-Dot - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-5: Vivelle-Dot - Recommended Dose (mg/Day Twice a Week)
  • Figure 10-6: Vivelle-Dot - Annual Sales (US$), 2020-2024
  • Figure 10-7: Minivelle - FDA Approval Year By Dose
  • Figure 10-8: Minivelle - FDA Approval & First Generic Approval Year
  • Figure 10-9: US - Minivelle Patent Issue & Expiration Year
  • Figure 10-10: Minnivelle - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-11: Minivelle - Recommended Dose By Indication (mg/Day)
  • Figure 10-12: Minivelle - Annual Sales (US$), 2020-2024
  • Figure 10-13: Climara - FDA Approval Year By Dose
  • Figure 10-14: Climara - FDA Approval & First Generic Approval Year
  • Figure 10-15: Climara - Price Per Unit & Supply In Canada (US$), February'2025
  • Figure 10-16: Menostar - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-17: FemSeven - Price Per Unit & Supply (Euro/US$), February'2025
  • Figure 10-18: FemSeven - Initial & Increased Dosage For Postmenopausal Symptoms (mg/hr)
  • Figure 10-19: Estrana - Price Per Supply (US$), February'2025
  • Figure 10-20: Estrana - Annual Sales (US$), 2020-2024
  • Figure 10-21: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Twice Weekly Patch In US (US$), March'2025
  • Figure 10-22: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Weekly Patch In US (US$), March'2025
  • Figure 10-23: Androderm - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-24: Androderm - Recommended Initial & Maintainence Dose For Treatment of Hypogonadism (mg/day)
  • Figure 10-25: Xulane - FDA Approval & First Generic Approval Year
  • Figure 10-26: Ortho Evara - FDA & EMA Approval Year
  • Figure 10-27: Xulane & Zafemy - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-28: Ethinyl Estradiol/Norelgestromin Patch - Recommended Schedule for Achieving Birth Control Effect (Days)
  • Figure 10-29: Evra - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 10-30: CombiPatch - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-31: CombiPatch - Price Per Unit & Supply In Canada (US$), February'2025
  • Figure 10-32: CombiPatch - Annual Sales (US$), 2020-2024
  • Figure 10-33: Estradiol/Levonorgestrel - Approval Year By Region
  • Figure 10-34: Climara Pro - Price Per Unit & Supply In US (US$), March'2025
  • Figure 10-35: FemSeven Conti - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 10-36: US - Twirla Patent Issue & Expiration Year
  • Figure 10-37: Twirla - Price Per Unit & Supply (US$), March'2025
  • Figure 10-38: Twirla - Recommended Schedule For Achieving Birth Control Effect (Days)
  • Figure 11-1: Transderm-Scop - FDA Approval & 1st Generic Approval Year
  • Figure 11-2: Transderm-Scop - Price Per Unit & Supply (US$), March'2025
  • Figure 11-3: Scopolamine - Price Per Unit & Supply (US$), March'2025
  • Figure 11-4: Emsam - Price Per Unit & Supply (US$), March'2025
  • Figure 11-5: Daytrana - FDA Approval & Patent Exclusivity Year
  • Figure 11-6: US - Daytrana Patent Issue & Expiration Year
  • Figure 11-7: Daytrana - Price Per Unit & Supply (US$), March'2025
  • Figure 11-8: Daytrana - Annual Sales (US$), 2020-2024
  • Figure 11-9: Xelstrym - Price Per Unit & Supply (US$), March'2025
  • Figure 11-10: Xelstrym - Annual Sales (US$), 2023-2024
  • Figure 11-11: Lonasen - Price Per Unit in Japan (US$), February'2025
  • Figure 11-12: US - Secuado Patent Issue & Expiration Year
  • Figure 11-13: Secuado - Price Per Unit & Supply (US$), March'2025
  • Figure 11-14: Secuado - Recommended Initial & Incremented Dose (mg/Day)
  • Figure 11-15: Secuado - Annual Sales (US$), 2020-2024
  • Figure 11-16: Exelon - Approval Year By Region
  • Figure 11-17: US - Exelon FDA Approval Year & 1st Generic Approval Year
  • Figure 11-18: Exelon - Price Per Unit & Supply In US (US$), March'2025
  • Figure 11-19: Generic Rivastigmine Patch - Price Per Unit & Supply (US$), March'2025
  • Figure 11-20: Neupro - Approval Year By Region
  • Figure 11-21: US - Neupro Approval Year By Indication
  • Figure 11-22: Neupro - Patent Issue & Expiration Year
  • Figure 11-23: Neupro - Price Per Unit & Supply (US$), March'2025
  • Figure 11-24: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
  • Figure 11-25: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day)
  • Figure 11-26: Neupro - Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
  • Figure 11-27: Global - Neupro Sales (US$ Million), 2020-2024
  • Figure 11-28: Haruropi Tape Patch - Price Per Unit In Japan (US$), February'2025
  • Figure 11-29: Haruropi Tape - Initial & Maximum Recommended Dose (mg/day)
  • Figure 11-30: Haruropi - Annual Sales (US$), 2020-2024
  • Figure 11-31: Adlarity - Price Per Unit & Supply In US (US$), February'2025
  • Figure 12-1: Nicotine Transdermal Patch - Approval Year By Region
  • Figure 12-2: Nicoderm CQ - Price Per Unit & Supply (US$), March'2025
  • Figure 12-3: Generic Nicotine Patch - Price Per Unit & Supply Of 7mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-4: Generic Nicotine Patch - Price Per Unit & Supply Of 14mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-5: Generic Nicotine Patch - Price Per Unit & Supply Of 21mg/24hr Transdermal Patches (US$), March'2025
  • Figure 12-6: Nicoderm CQ - Recommended Dose & Treatment Schedule For Patients with Consumption More Than 10 Cigarette/Days (mg/day)
  • Figure 12-7: Oxybutynin Transdermal Patch - Approval Year By Region
  • Figure 12-8: Oxytrol - Price Per Unit & Supply In US (US$), March'2025
  • Figure 12-9: Kentera - Price Per Unit & Supply In UK (US$), February'2025
  • Figure 12-10: Sancuso - Approval Year By Region
  • Figure 12-11: US - Sancuso Patent Issue & Expiration Year
  • Figure 12-12: Allesaga - Price Per Unit By Dose (US$), February'2025
  • Figure 12-13: Allesaga - Initial & Maximum Recommended Dose (mg/hr)
  • Figure 12-14: Allesaga - Annual Sales (US$), 2020-2023
  • Figure 12-15: Tulo-Touch - Price Per Unit By Dose (US$), February'2025
  • Figure 12-16: Hokunalin - Price Per Unit By Dose (US$), February'2025
  • Figure 13-1: Global Transdermal Patch Market - Favorable Parameters
  • Figure 13-2: Global Transdermal Patch Market - Commercialization Challenges

List of Tables

  • Table 2-1: Active v/s Passive Transdermal Patch
  • Table 3-1: Transdermal Patches For Various Disease Indications
  • Table 9-1: Duragesic - Initial Dose Conversion From Other Opioids
  • Table 9-2: Butrans - Initial Dose Calculation Using Previous Opioid (Morphine) Dosage
  • Table 11-1: Daytrana - Dose Increment Pattern For Treatment Of ADHD